Voyager Therapeutics Announces Appointment of Beth Shafer as Chief Business Officer
07 Août 2023 - 2:00PM
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology
company dedicated to breaking through barriers in gene therapy and
neurology, today announced the appointment of Beth Shafer, Ph.D.,
M.A., M.Phil., as Chief Business Officer (CBO). Shafer is a
seasoned healthcare executive with more than 15 years of experience
in corporate and business development at prominent
biopharmaceutical companies, as well as deep knowledge in
neurology. She most recently served as Vice President and Head of
R&D Business Development, Gastrointestinal & Inflammation,
Neuroscience, Drug Discovery Sciences, Externalizations at Takeda
Pharmaceutical Company Ltd.
“Voyager’s TRACER™ capsid platform and neurology programs
continue to attract significant interest from third parties,” said
Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of
Voyager. “Beth has extensive experience in business development and
strategic planning, and we look forward to the valuable insights
she will bring both in optimizing the opportunities in front of us
today and in helping Voyager to maximize value creation for
patients and for shareholders into the future.”
In her most recent role at Takeda, Shafer was responsible for
leading business development groups and activities in several core
areas, including neuroscience, gastroenterology, drug discovery
sciences, and R&D pipeline externalizations. Notably, she
secured licenses and collaborations that grew Takeda’s neuroscience
pipeline from a small molecule psychiatry focus into a rare
neurology diversified multi-modality portfolio. She previously held
multiple corporate and business development roles of increasing
responsibility during her tenures at Takeda, Novartis and Roche.
Prior to joining Takeda, Shafer served as Head, Ophthalmology and
Disease Area X Business Development & Licensing at Novartis
Institutes for Biomedical Research, where she helped drive and
shape the organization’s portfolio and research strategies by
creating and executing on external partnership solutions. Prior to
that role, she served as Director, Business Development &
Licensing at Roche, where she built the business development
process for the External Development Group and led cross-functional
pharmaceutical project and deal teams for several therapeutic
areas, serving integral roles from strategy to deal execution.
Shafer received her Ph.D. in Neuroscience from University of
California, San Diego, her M.Phil. and M.A from Columbia University
Vagelos College of Physicians and Surgeons, and her B.A. from
Rutgers University.
“I am thrilled to have this opportunity to join the Voyager team
and combine my deep focus in neuroscience with my passion for
scientific innovations, including disruptive modalities with the
potential to bring transformative benefit to patients,” said
Shafer. “I look forward to helping the team leverage business
development and strategy to achieve its mission of advancing
life-changing genetic medicines for neurological diseases.”
About Voyager TherapeuticsVoyager
Therapeutics (Nasdaq: VYGR) is a biotechnology company dedicated to
breaking through barriers in gene therapy and neurology. The
potential of both disciplines has been constrained by delivery
challenges; Voyager is leveraging cutting-edge expertise in capsid
discovery and deep neuropharmacology capabilities to address these
constraints. Voyager’s TRACER AAV capsid discovery platform has
generated novel capsids with high target delivery and blood-brain
barrier penetration at low doses, potentially addressing the narrow
therapeutic window associated with conventional gene therapy
delivery vectors. This platform is fueling alliances with Pfizer
Inc., Novartis Pharma AG, Neurocrine Biosciences, Inc., and Sangamo
Therapeutics, Inc., as well as multiple programs in Voyager’s own
pipeline. Voyager’s pipeline includes wholly-owned and
collaborative preclinical programs in Alzheimer’s disease,
amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and other
diseases of the central nervous system, with a focus on validated
targets and biomarkers to enable a path to rapid potential
proof-of-biology. For more information, visit
www.voyagertherapeutics.com.
Voyager Therapeutics® is a registered trademark, and
TRACER™ is a trademark, of Voyager Therapeutics,
Inc.
Forward-Looking StatementsThis press release
contains forward-looking statements for the purposes of the safe
harbor provisions under The Private Securities Litigation Reform
Act of 1995 and other federal securities laws. The use of words
such as “will,” “intend,” “future,” “potential,” or “continue,” and
other similar expressions are intended to identify forward-looking
statements.
For example, all statements Voyager makes regarding the
contributions Shafer may make in her role with respect to
optimizing business opportunities for Voyager, and Voyager helping
to maximize value creation for patients and shareholders, are
forward-looking.
All forward-looking statements are based on estimates and
assumptions by Voyager’s management that, although Voyager believes
such forward-looking statements to be reasonable, are inherently
uncertain. All forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially
from those that Voyager expected. Such risks and uncertainties
include, among others, the ability of Voyager to optimize its
business opportunities and maximize value creation for patients and
shareholders; the continued development by Voyager of its platform
technology and pipeline programs and the timing thereof; and the
sufficiency of Voyager’s cash resources to fund its operations and
corporate objectives.
These statements are also subject to a number of material risks
and uncertainties that are described in Voyager’s most recent
Annual Report on Form 10-K filed with the Securities and Exchange
Commission, as updated by its subsequent filings with the
Securities and Exchange Commission. All information in this press
release is as of the date of this press release, and any
forward-looking statement speaks only as of the date on which it
was made. Voyager undertakes no obligation to publicly update or
revise this information or any forward-looking statement, whether
as a result of new information, future events or otherwise, except
as required by law.
Contacts
Investors: Andrew
Funderburkafunderburk@kendallir.com
Media: Peg Rusconiprusconi@vergescientific.com
Voyager Therapeutics (NASDAQ:VYGR)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Voyager Therapeutics (NASDAQ:VYGR)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024